Brian Slomovitz

14PUBLICATIONS

86CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer diagnosisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (14)

Sort by Publication Date:

|Jul 10, 2026

Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

|Dec 12, 2025

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Brian M Slomovitz, S John Weroha, Wei Deng

|Dec 02, 2025

Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.

Vivek Podder, Robert L Coleman, Andrea R Hagemann

|May 16, 2025

Comprehensive management of vulvovaginal cancers.

Angélica Nogueira-Rodrigues, Maaike H M Oonk, Domenica Lorusso

|Apr 26, 2025

Examining the Association of Body Mass Index and Complications When Including Sentinel Lymph Node Biopsy in Minimally Invasive Surgery for Endometrial Intraepithelial Neoplasia.

Gabriel Levin, Pedro T Ramirez, Jason D Wright

|Oct 16, 2024

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Brian M Slomovitz, David Cibula, Weiguo Lv

Pageof 3

Frequent Collaborators

Bradley J Monk

Robert L Coleman

Thomas J Herzog

Bhavana Pothuri

Isabelle Ray-Coquard

David M Gershenson

Toon Van Gorp

Shannon N Westin

Domenica Lorusso

David Cibula

Frequent Collaborators

Bradley J Monk

Robert L Coleman

Thomas J Herzog

Bhavana Pothuri